Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [Phase 2]
Phase 2 trial evaluating modified release AFQ056 for Parkinson's patients with L-dopa induced dyskinesias has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [Phase 2]
Phase 2 trial evaluating AFQ056 for L-dopa induced dyskinesias in Parkinson's patients completed.
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [Phase 2]
Open-label Phase 2 trial assessing AFQ056 for safety, tolerability, and efficacy in Parkinson's patients with L-dopa induced dyskinesias com…
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia [Phase 2]
Phase 2 trial update evaluating AFQ056 with higher L-dopa doses in Parkinson's disease patients with moderate-severe L-dopa induced dyskines…
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [Phase 2]
Phase 2 long-term safety extension study update for AFQ056 in Parkinson's patients with L-dopa-induced dyskinesias.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Vibration Impact on Parkinson's Tremor [NA]
A completed clinical trial evaluating vibration impact on tremor in Parkinson disease; results posted December 17, 2020.
-
FDA approval · 2020-12-11FDA Approved: FLUORODOPA F18 — Supplemental Application (THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH)
FDA approved a supplemental application for Fluorodopa F18, enabling updated labeling/indications for its use in brain PET imaging. The appr…
-
CLINICAL_TRIALS trial_result · 2020-12-09Clinical Trial Update: Cognitive Dysfunction in Parkinson's Disease [NA]
A completed clinical trial investigating cognitive dysfunction in Parkinson's disease; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-12-01Clinical Trial Update: Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness [Phase 2]
Phase 2 trial update on THN102 for Parkinson's disease with excessive daytime sleepiness; results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-24Clinical Trial Update: BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness [Phase 2]
Phase 2 trial of BEN-2001 in Parkinson's disease patients with excessive daytime sleepiness has completed and results have been posted.
-
FDA approval · 2020-11-23FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)
The FDA approved a supplemental application for Nuplazid (pimavanserin tartrate) submitted by Acadia Pharmaceuticals Inc., updating the labe…
-
FDA label_change · 2020-11-23FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)
FDA approved a supplemental application for Nuplazid (pimavanserin tartrate) from Acadia Pharmaceuticals, resulting in updated labeling.
-
CLINICAL_TRIALS trial_result · 2020-11-23Clinical Trial Update: An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients [Phase 2]
Open-label phase 2 safety study evaluating pimavanserin in Parkinson's disease psychosis completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-11-23Clinical Trial Update: A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease [Phase 2]
Phase 2 clinical trial evaluating SAGE-217 in participants with Parkinson's disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-20Clinical Trial Update: A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease [Phase 3]
This document reports a 12-week, randomized Phase 3 study evaluating oral istradefylline as add-on therapy in adults with moderate to severe…
-
CLINICAL_TRIALS trial_result · 2020-11-19Clinical Trial Update: Clinical Evaluation of the Infinity Deep Brain Stimulation System
Abbott Medical Devices completed the clinical evaluation of the Infinity Deep Brain Stimulation System for Parkinson disease and posted resu…
-
FDA approval · 2020-11-10FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for pramipexole dihydrochloride from Macleods Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2020-11-04Clinical Trial Update: Effects of Transcranial Direct Current Stimulation on Postural Control [Phase 2, Phase 3]
Phase 2/3 trial investigating transcranial direct current stimulation for postural control in Parkinson disease has completed.
-
FDA approval · 2020-10-29FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for pramipexole dihydrochloride from Macleods Pharmaceuticals Limited. This action confirms regu…
-
FDA approval · 2020-10-16FDA Approved: RASAGILINE — Supplemental Application (Alvogen, Inc.)
FDA approved a supplemental application for Rasagiline by Alvogen, Inc., resulting in an approved supplemental application for the generic d…
-
FDA approval · 2020-10-16FDA Approved: RASAGILINE — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for Rasagiline from Micro Labs Limited. It confirms regulatory authorization for a generic rasagilin…
-
FDA approval · 2020-10-15FDA Approved: AMANTADINE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original application for amantadine, allowing a generic version to enter the market.
-
FDA approval · 2020-10-14FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for Pramipexole dihydrochloride from Dr. Reddy's Laboratories Limited under the ANDA program.
-
CLINICAL_TRIALS trial_result · 2020-10-09Clinical Trial Update: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease [NA]
A completed clinical trial investigating ExAblate transcranial MR-guided focused ultrasound for Parkinson's disease, with results posted in …
-
CLINICAL_TRIALS trial_result · 2020-10-01Clinical Trial Update: Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS [NA]
A completed clinical trial investigated the long-term effects of Low Frequency Stimulation on aspiration and freezing of gait in Parkinson's…